Precautions before taking Futibatinib

Futibatinib is a targeted drug used to treat advanced or metastatic cholangiocarcinoma (CCA). Despite its remarkable efficacy, there are some potential adverse effects that require close attention when using forbatinib. Here are a few key things to note before using forbatinib:

1. Eye toxicity: Retinal pigment epithelial detachment (RPED)

Forbatinib may cause retinal pigment epithelial detachment (RPED), an eye disease that affects vision and may cause symptoms such as blurred vision. To ensure early detection of such side effects, it is recommended that patients undergo a comprehensive ophthalmological examination, particularly optical coherence tomography (OCT) of the macula, every 2 months for the first 6 months before starting treatment. After 6 months, the frequency of eye exams should be reduced to every 3 months. If patients develop any visual symptoms, they must undergo an ophthalmological evaluation immediately and follow up every 3 weeks until symptoms resolve or the drug is discontinued. When symptoms of RPED occur, doctors can suspend or adjust the dose of forbatinib as needed. In addition, dry eye syndrome and keratitis are also common ocular adverse reactions. Ocular analgesics may be used to relieve symptoms.

2. Hyperphosphatemia and soft tissue mineralization

Forbatinib may also cause hyperphosphatemia, which may further lead to soft tissue mineralization, calcium deposition, vascular calcification and other problems. One of the pharmacodynamic effects of forbatinib is to increase phosphate levels, which can lead to the side effects mentioned above. To avoid or reduce complications from hyperphosphatemia, monitor serum phosphate levels regularly during treatment. If phosphate levels≥5.5mg/dL, a low-phosphate diet should be started immediately and treatment with phosphate-lowering drugs should be considered. When the serum phosphorus level exceeds 7 mg/dL, the intensity of phosphorus-lowering treatment should be increased, and the dose of forbatinib should be adjusted or its use suspended according to the situation. If necessary, the drug can be permanently discontinued. Dose adjustment is very important in patients with high and persistent phosphate levels.

3. Embryo-fetal toxicity

Forbatinib has been shown to be potentially harmful to the fetus in animal studies. Fetal malformations, growth retardation, and fetal death have been observed during organogenesis in pregnant rats at doses lower than clinical doses of forbatinib used in humans. Therefore, pregnant women and women who may become pregnant should use special caution when using forbatinib.

The use of forbatinib will cause certain harm to the fetus. Therefore, all female patients with reproductive potential must be treated during treatment and after the last doseUse effective contraception within 1 week. Similarly, for male patients, if their partner is of childbearing potential, they should also use contraception during treatment and within 1 week after the last dose to prevent potential risks to the fetus.

Prior to treatment, patients should be informed of the potential fetal toxicity of forbatinib and discuss relevant contraceptive methods with their physician. If the patient is pregnant or planning to become pregnant, the doctor should be informed immediately so that appropriate measures can be taken to ensure the safety of mother and baby.

When using forbatinib, patients should always pay attention to possible eye toxicity, hyperphosphatemia, embryo-fetal toxicity and other issues, and make corresponding monitoring and adjustments according to the guidance of the doctor. The therapeutic effect of forbatinib is significant, but during use, regular eye examinations, monitoring of blood phosphorus levels, and appropriate contraceptive measures are required to ensure the safety of the treatment.

Reference materials:https://www.lytgobi.com/